Abstract:A certain number of pediatric cancer patients still succumb to relapse following conventional treatment of their malignancies. One of the mechanisms of relapse is escape from immunity. Adoptive cellular immunotherapy with effector cells has the potential to overcome this escape. In adults, the CD3+ CD56+ cell, a cytokine-induced killer (CIK) cell, appears to be a promising effector cell type with the greatest cytotoxicity. This effector cell type may work in children as well. No similar studies with children have been published. We speculated that expanded CD3+ CD56+ cells obtained from pediatric cancer patients during remission would act similarly against various pediatric tumor cell lines; therefore, we undertook the present study to find support for our speculation. This study was undertaken to generate and expand CD3+ CD56+ CIK cells from normal peripheral blood mononuclear cells (PBL) obtained from 6 children with cancer (2 with acute lymphoblastic leukemia, 2 with large cell lymphoma, and 2 with osteosarcoma) in remission after intensive chemotherapy and to study the cytotoxic activities of these cells against chronic myeloid leukemia cell line K562 t(9;22), 4 pediatric tumor cell lines [infant acute lymphoblastic leukemia RS4 t(4;11), TEL/AML acute lymphoblastic leukemia REH t(12;21), alveolar rhabdomyosarcoma Rh-Cr t(2;13), and Ewing sarcoma EW-Le t(11;22)], and 2 pediatric glioblastoma multiforme cultured cell lines (G74 and G77). CIK cells were generated and expanded in culture medium to which interferon gamma, monoclonal antibody against CD3, and interleukin 2 were added at appropriate times. Cells were counted by flow cytometry. Net lactate dehydrogenase release from target cells incubated with CIK cells was used as an index of CIK cell cytotoxicity against various pediatric tumor cell lines. The results show that after 21 days in culture CD3+ CD56+ CIK cells derived from the 6 pediatric patients accounted for a median of 28.3% of the entire culture (range, 10.7%-36.4%). Before expansion no such cells were found in any of the 6 children. Median lytic activity rates of CIK cells were 45.5% to 64.5%, rates that contrasted drastically to the lytic activity rates of PBL, which were only 8% to 12%. The findings of the present study are encouraging. They provide information for developing adoptive immunotherapy for future clinical trials with pediatric cancer patients, particularly those patients with minimal residual disease after intensive chemotherapy or stem cell transplantation (especially nonmyeloablative transplantation procedures).

Generation of Large Numbers of Dendritic Cells and Cytokine-induced Killer Cells from Breast Cancer Patients

Efficient Expansion of the Cytokine-Induced Natural Killer Cells from Human Peripheral Blood in Vitro

New Method in Vitro for Large Expansion of CIK Cells from 50 Ml Peripheral Blood for Clinical Therapy

In Vitro Rapid Generation and Application of Mature Dendritic Cells from Peripheral Blood Cells of Patient with Melanoma

Generation and Functional Characterization of Dendritic Cell from Peripheral Mononuclear Cells of Patients with Solid Tumors in the Presence of Autologous Plasma

Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells

Inducing Large Numbers of Dendritic Cells from Primary Cells of Chronic Myeloid Leukemia and the Function Research

Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis.

Establishment of Large-Capacity Culture Method of CIK Cells from Cord Blood

Enhanced Cytotoxicity And Underlying Mechanism Of Ex Vivo Expanded Natural Killer Cells Against Breast Cancer Cells

The Clinical Research of Cytokine-induced Killer Cells Co-culturing with Autologous Dendritic Cells on the Clinical Immunotherapy for

Immunobiologic Properties of Dendritic Cells Derived from G-CSF Mobilized Peripheral Blood

[Large-Capacity Expanded Cytoline-Induced Killer Cells and Its Cytotoxic Activity].

2003-2013, a Valuable Study: Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Stage IV Breast Cancer.

Study on the Kill Activity of the Whole Tumor Cell Antigen Pulsed DC Co-Culture with CIK for Breast Cancer Circulating Tumor Cells

Augmented CD3(+)CD8(+) and CD3(+)CD56(-) cells in cytokine-induced killer cells cultured with engineered cells for costimulatory enhancement from heavily pretreated patients with solid tumor.

Cytokine-induced Killer Cells Promote Antitumor Immunity

Generation and Characterization of Antitumor Infiltrating Lymphocytes from Patients with Breast Cancer for Adoptive Cell Transfer Therapy

Preparation of DC-CIK Using EBV Peptide-Pulsed DC from Peripheral Blood Mononuclear Cells of Post-Transplant Lymphoproliferative Disorder Patients after Hematopoietic Stem Cell Transplantation

Phenotypic Characterization And Anticancer Capacity Of Cd8+Cytokine-Induced Killer Cells After Antigen-Induced Expansion

Expansion of CIK cells from cryopreserved peripheral blood progenitor cells and their anti-tumor effect in vitro